Murilo De Almeida Luz MD

Urology•New York, NY

Urologic Oncologist at The Mount Sinai Hospital

Join to View Full Profile

1 Gustave L Levy Pl# 1272New York, NY 10029
Phone+1 212-241-9955
Fax+1 212-241-4812

Summary

Urologic Oncologist dedicated to treatment and research of all urological malignancies (prostate, bladder, kidney, testis and penile cancer). Experient robotic surgeon with more than 2000 cases performed. Very prolific investigator with several important publications including 3 New England Journal of Medicine papers in the last 5 years.

Education & Training

McGill UniversityMinimally Invasive / Robotics in Urology, 2010 - 2011
McGill UniversityUrologic Oncology, 2008 - 2010
Erasto Gaertner HospitalSpecialist, Surgical Oncology, 2006 - 2008
University of Sao PauloSpecialist, General Surgery, 2004 - 2006
Universidade Federal do ParanáClass of 2002

Certifications & Licensure

NY State Medical License 2024 - 2026
Brazilian College of SurgeonsGeneral Surgery Board Certification
Brazilian Society of Surgical OncologySurgical Oncology Board Certification
Brazilian Society of UrologyUrology Board Certification

Awards, Honors, & Recognition

Mario de Abreu Award - Best Grades in Surgical Disciplines UFPR, 2002

Clinical Trials

Antibiotic Prophylaxis Before Shock Wave Lithotripsy Start of enrollment: 2018 Sep 27
COMPLETED
PHASE4
Roles: Contact
Evaluation of an Active Surveillance Protocol for Prostate Cancer in the Brazilian Population Start of enrollment: 2022 Aug 19
Recruiting
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Start of enrollment: 2014 Dec 17
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies Start of enrollment: 2023 Apr 03
RECRUITING
PHASE3
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer Start of enrollment: 2014 Sep 12
Completed
Phase 3
Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels Start of enrollment: 2017 Oct 11
Completed
Phase 2
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations Start of enrollment: 2018 Mar 23
ACTIVE_NOT_RECRUITING
PHASE3
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Start of enrollment: 2013 Oct 31
ACTIVE_NOT_RECRUITING
PHASE3
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Start of enrollment: 2015 Nov 19
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

10 citations
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
Fred Saad, Egils Vjaters, Neal Shore, David Olmos, Nianzeng Xing
Journal of Clinical Oncology. 2024-12-20
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American ...
Vinicius Carrera Souza, Fernando Sabino Marques Monteiro, Fernando Cotait Maluf, Gustavo Werutsky, Vanessa de Carvalho Fabrício
Clinical Genitourinary Cancer. 2024-10-01
1 citations
PSMA PET/CT in the Brazilian Unified Healthcare System reduces costs with futile salvage therapies in the management of cases of biochemical recurrence of prostate can...
Mateos Bogoni, Juliano Julio Cerci, Evelinda Marramon Trindade, Miguel Morita Fernandes da Silva, Marina Bicalho Silveira
Radiologia Brasileira. 2024-08-31